nodes	percent_of_prediction	percent_of_DWPC	metapath
Fludarabine—DCK—Pyrimidine metabolism—NT5C3A—bone cancer	0.0307	0.0763	CbGpPWpGaD
Fludarabine—POLA1—Leading Strand Synthesis—RFC1—bone cancer	0.0226	0.0563	CbGpPWpGaD
Fludarabine—RRM1—Nucleotide Metabolism—DHFR—bone cancer	0.0195	0.0485	CbGpPWpGaD
Fludarabine—POLA1—Lagging Strand Synthesis—RFC1—bone cancer	0.0164	0.0407	CbGpPWpGaD
Fludarabine—RRM1—Nucleotide metabolism—NT5C3A—bone cancer	0.0155	0.0386	CbGpPWpGaD
Fludarabine—POLA1—Telomere C-strand (Lagging Strand) Synthesis—RFC1—bone cancer	0.0152	0.0378	CbGpPWpGaD
Fludarabine—POLA1—Extension of Telomeres—RFC1—bone cancer	0.0126	0.0314	CbGpPWpGaD
Fludarabine—RRM1—Fluoropyrimidine Activity—DHFR—bone cancer	0.0126	0.0312	CbGpPWpGaD
Fludarabine—POLA1—G1/S-Specific Transcription—DHFR—bone cancer	0.012	0.0299	CbGpPWpGaD
Fludarabine—DCK—Nucleotide metabolism—NT5C3A—bone cancer	0.0119	0.0297	CbGpPWpGaD
Fludarabine—POLA1—DNA strand elongation—RFC1—bone cancer	0.0117	0.0291	CbGpPWpGaD
Fludarabine—SLC29A1—Fluoropyrimidine Activity—DHFR—bone cancer	0.0115	0.0285	CbGpPWpGaD
Fludarabine—POLA1—Nucleotide Metabolism—DHFR—bone cancer	0.011	0.0273	CbGpPWpGaD
Fludarabine—POLA1—DNA Replication—RFC1—bone cancer	0.0094	0.0234	CbGpPWpGaD
Fludarabine—POLA1—Inhibition of replication initiation of damaged DNA by RB1/E2F1—RB1—bone cancer	0.00725	0.018	CbGpPWpGaD
Fludarabine—POLA1—E2F mediated regulation of DNA replication—DHFR—bone cancer	0.00707	0.0176	CbGpPWpGaD
Fludarabine—DCK—Doxorubicin—Epirubicin—bone cancer	0.00696	0.519	CbGdCrCtD
Fludarabine—RRM1—E2F transcription factor network—DHFR—bone cancer	0.00665	0.0165	CbGpPWpGaD
Fludarabine—DCK—Epirubicin—Doxorubicin—bone cancer	0.00644	0.481	CbGdCrCtD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—DHFR—bone cancer	0.00578	0.0144	CbGpPWpGaD
Fludarabine—POLA1—Telomere Maintenance—RFC1—bone cancer	0.00573	0.0142	CbGpPWpGaD
Fludarabine—POLA1—Synthesis of DNA—RFC1—bone cancer	0.00485	0.0121	CbGpPWpGaD
Fludarabine—POLA1—Chromosome Maintenance—RFC1—bone cancer	0.00477	0.0119	CbGpPWpGaD
Fludarabine—POLA1—DNA Replication—RFC1—bone cancer	0.00455	0.0113	CbGpPWpGaD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—DHFR—bone cancer	0.00445	0.0111	CbGpPWpGaD
Fludarabine—POLA1—S Phase—RFC1—bone cancer	0.00398	0.0099	CbGpPWpGaD
Fludarabine—POLA1—E2F transcription factor network—DHFR—bone cancer	0.00375	0.00931	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.0037	0.00921	CbGpPWpGaD
Fludarabine—RRM1—E2F transcription factor network—PLAU—bone cancer	0.0037	0.00919	CbGpPWpGaD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—DHFR—bone cancer	0.00326	0.00809	CbGpPWpGaD
Fludarabine—POLA1—E2F mediated regulation of DNA replication—RB1—bone cancer	0.00323	0.00803	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.00315	0.00783	CbGpPWpGaD
Fludarabine—RRM1—E2F transcription factor network—RB1—bone cancer	0.00304	0.00755	CbGpPWpGaD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—CDK4—bone cancer	0.00304	0.00755	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.00287	0.00713	CbGpPWpGaD
Fludarabine—RRM1—Fluoropyrimidine Activity—TP53—bone cancer	0.0028	0.00697	CbGpPWpGaD
Fludarabine—POLA1—G1/S Transition—DHFR—bone cancer	0.00272	0.00676	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.00267	0.00664	CbGpPWpGaD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—RB1—bone cancer	0.00264	0.00656	CbGpPWpGaD
Fludarabine—POLA1—Mitotic M-M/G1 phases—ZW10—bone cancer	0.00264	0.00656	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.00261	0.00649	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.00258	0.0064	CbGpPWpGaD
Fludarabine—SLC29A1—Fluoropyrimidine Activity—TP53—bone cancer	0.00257	0.00638	CbGpPWpGaD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—CDK4—bone cancer	0.00234	0.00581	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.0023	0.00573	CbGpPWpGaD
Fludarabine—POLA1—Mitotic G1-G1/S phases—DHFR—bone cancer	0.00229	0.0057	CbGpPWpGaD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—MDM2—bone cancer	0.00225	0.0056	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.00218	0.00543	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.00209	0.00519	CbGpPWpGaD
Fludarabine—POLA1—E2F transcription factor network—PLAU—bone cancer	0.00208	0.00518	CbGpPWpGaD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—RB1—bone cancer	0.00203	0.00505	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.00199	0.00495	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—ZW10—bone cancer	0.00197	0.0049	CbGpPWpGaD
Fludarabine—Blood uric acid increased—Epirubicin—bone cancer	0.0018	0.00308	CcSEcCtD
Fludarabine—Hypocalcaemia—Doxorubicin—bone cancer	0.00179	0.00306	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.00177	0.00441	CbGpPWpGaD
Fludarabine—Hyperuricaemia—Doxorubicin—bone cancer	0.00177	0.00302	CcSEcCtD
Fludarabine—POLA1—Cell Cycle—ZW10—bone cancer	0.00176	0.00438	CbGpPWpGaD
Fludarabine—Hyperkalaemia—Epirubicin—bone cancer	0.00174	0.00298	CcSEcCtD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—MDM2—bone cancer	0.00173	0.00431	CbGpPWpGaD
Fludarabine—Coma—Methotrexate—bone cancer	0.00173	0.00296	CcSEcCtD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.00172	0.00427	CbGpPWpGaD
Fludarabine—POLA1—E2F transcription factor network—RB1—bone cancer	0.00171	0.00425	CbGpPWpGaD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—CDK4—bone cancer	0.00171	0.00425	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—NDUFA12—bone cancer	0.0017	0.00423	CbGpPWpGaD
Fludarabine—Visual impairment—Cisplatin—bone cancer	0.00167	0.00285	CcSEcCtD
Fludarabine—Blood uric acid increased—Doxorubicin—bone cancer	0.00167	0.00285	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.00162	0.00402	CbGpPWpGaD
Fludarabine—Coma—Epirubicin—bone cancer	0.00162	0.00277	CcSEcCtD
Fludarabine—Oesophagitis—Epirubicin—bone cancer	0.00162	0.00277	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.00161	0.00402	CbGpPWpGaD
Fludarabine—Hyperkalaemia—Doxorubicin—bone cancer	0.00161	0.00275	CcSEcCtD
Fludarabine—Arrhythmia—Cisplatin—bone cancer	0.00155	0.00265	CcSEcCtD
Fludarabine—Alopecia—Cisplatin—bone cancer	0.00153	0.00262	CcSEcCtD
Fludarabine—Hepatic failure—Methotrexate—bone cancer	0.00153	0.00261	CcSEcCtD
Fludarabine—Malnutrition—Cisplatin—bone cancer	0.00151	0.00258	CcSEcCtD
Fludarabine—Coma—Doxorubicin—bone cancer	0.0015	0.00256	CcSEcCtD
Fludarabine—Oesophagitis—Doxorubicin—bone cancer	0.0015	0.00256	CcSEcCtD
Fludarabine—POLA1—Cell Cycle, Mitotic—TUBB4B—bone cancer	0.00149	0.00372	CbGpPWpGaD
Fludarabine—Phlebitis—Epirubicin—bone cancer	0.00149	0.00255	CcSEcCtD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—RB1—bone cancer	0.00149	0.0037	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.00147	0.00366	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.00145	0.00361	CbGpPWpGaD
Fludarabine—Visual disturbance—Methotrexate—bone cancer	0.00145	0.00248	CcSEcCtD
Fludarabine—Hepatic failure—Epirubicin—bone cancer	0.00143	0.00245	CcSEcCtD
Fludarabine—Cardiac failure congestive—Epirubicin—bone cancer	0.00142	0.00242	CcSEcCtD
Fludarabine—RRM1—Metabolism—NT5C3A—bone cancer	0.00141	0.00351	CbGpPWpGaD
Fludarabine—Cerebrovascular accident—Methotrexate—bone cancer	0.0014	0.0024	CcSEcCtD
Fludarabine—Ill-defined disorder—Cisplatin—bone cancer	0.0014	0.00239	CcSEcCtD
Fludarabine—Anaemia—Cisplatin—bone cancer	0.00139	0.00238	CcSEcCtD
Fludarabine—Phlebitis—Doxorubicin—bone cancer	0.00138	0.00236	CcSEcCtD
Fludarabine—POLA1—Synthesis of DNA—RB1—bone cancer	0.00137	0.00342	CbGpPWpGaD
Fludarabine—Malaise—Cisplatin—bone cancer	0.00136	0.00233	CcSEcCtD
Fludarabine—POLA1—Cell Cycle, Mitotic—RFC1—bone cancer	0.00136	0.00337	CbGpPWpGaD
Fludarabine—Leukopenia—Cisplatin—bone cancer	0.00135	0.00231	CcSEcCtD
Fludarabine—POLA1—Cell Cycle—TUBB4B—bone cancer	0.00134	0.00332	CbGpPWpGaD
Fludarabine—Hepatic failure—Doxorubicin—bone cancer	0.00132	0.00226	CcSEcCtD
Fludarabine—Cardiac failure—Epirubicin—bone cancer	0.00132	0.00225	CcSEcCtD
Fludarabine—Cerebrovascular accident—Epirubicin—bone cancer	0.00131	0.00224	CcSEcCtD
Fludarabine—Cardiac failure congestive—Doxorubicin—bone cancer	0.00131	0.00224	CcSEcCtD
Fludarabine—DCK—Metabolism—NDUFA12—bone cancer	0.00131	0.00326	CbGpPWpGaD
Fludarabine—Convulsion—Cisplatin—bone cancer	0.00131	0.00223	CcSEcCtD
Fludarabine—POLA1—S Phase—CDK4—bone cancer	0.0013	0.00322	CbGpPWpGaD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—TP53—bone cancer	0.00129	0.00321	CbGpPWpGaD
Fludarabine—POLA1—DNA Replication—RB1—bone cancer	0.00129	0.00321	CbGpPWpGaD
Fludarabine—Gastrointestinal haemorrhage—Epirubicin—bone cancer	0.00129	0.0022	CcSEcCtD
Fludarabine—Myalgia—Cisplatin—bone cancer	0.00128	0.0022	CcSEcCtD
Fludarabine—Liver function test abnormal—Methotrexate—bone cancer	0.00127	0.00217	CcSEcCtD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—MDM2—bone cancer	0.00127	0.00315	CbGpPWpGaD
Fludarabine—Discomfort—Cisplatin—bone cancer	0.00127	0.00217	CcSEcCtD
Fludarabine—POLA1—G1/S Transition—RB1—bone cancer	0.00124	0.00309	CbGpPWpGaD
Fludarabine—Toxic epidermal necrolysis—Methotrexate—bone cancer	0.00124	0.00212	CcSEcCtD
Fludarabine—Anaphylactic shock—Cisplatin—bone cancer	0.00123	0.0021	CcSEcCtD
Fludarabine—Oedema—Cisplatin—bone cancer	0.00123	0.0021	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.00123	0.00306	CbGpPWpGaD
Fludarabine—Infection—Cisplatin—bone cancer	0.00122	0.00209	CcSEcCtD
Fludarabine—Cardiac failure—Doxorubicin—bone cancer	0.00122	0.00208	CcSEcCtD
Fludarabine—Cerebrovascular accident—Doxorubicin—bone cancer	0.00121	0.00208	CcSEcCtD
Fludarabine—POLA1—Cell Cycle—RFC1—bone cancer	0.00121	0.00301	CbGpPWpGaD
Fludarabine—Nervous system disorder—Cisplatin—bone cancer	0.00121	0.00206	CcSEcCtD
Fludarabine—Thrombocytopenia—Cisplatin—bone cancer	0.0012	0.00206	CcSEcCtD
Fludarabine—POLA1—Mitotic G1-G1/S phases—CDK4—bone cancer	0.0012	0.00299	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	0.0012	0.00298	CbGpPWpGaD
Fludarabine—Dehydration—Epirubicin—bone cancer	0.0012	0.00205	CcSEcCtD
Fludarabine—Gastrointestinal haemorrhage—Doxorubicin—bone cancer	0.00119	0.00203	CcSEcCtD
Fludarabine—Hyperhidrosis—Cisplatin—bone cancer	0.00119	0.00203	CcSEcCtD
Fludarabine—Liver function test abnormal—Epirubicin—bone cancer	0.00119	0.00203	CcSEcCtD
Fludarabine—Anorexia—Cisplatin—bone cancer	0.00117	0.00201	CcSEcCtD
Fludarabine—Toxic epidermal necrolysis—Epirubicin—bone cancer	0.00116	0.00198	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	0.00116	0.00288	CbGpPWpGaD
Fludarabine—Pancytopenia—Methotrexate—bone cancer	0.00113	0.00193	CcSEcCtD
Fludarabine—POLA1—S Phase—RB1—bone cancer	0.00113	0.0028	CbGpPWpGaD
Fludarabine—Musculoskeletal discomfort—Cisplatin—bone cancer	0.00112	0.00192	CcSEcCtD
Fludarabine—Dysphagia—Epirubicin—bone cancer	0.00111	0.0019	CcSEcCtD
Fludarabine—Neutropenia—Methotrexate—bone cancer	0.00111	0.0019	CcSEcCtD
Fludarabine—Dysuria—Methotrexate—bone cancer	0.00111	0.0019	CcSEcCtD
Fludarabine—Dehydration—Doxorubicin—bone cancer	0.00111	0.00189	CcSEcCtD
Fludarabine—Paraesthesia—Cisplatin—bone cancer	0.0011	0.00189	CcSEcCtD
Fludarabine—Upper respiratory tract infection—Methotrexate—bone cancer	0.0011	0.00189	CcSEcCtD
Fludarabine—Liver function test abnormal—Doxorubicin—bone cancer	0.0011	0.00188	CcSEcCtD
Fludarabine—Dyspnoea—Cisplatin—bone cancer	0.0011	0.00188	CcSEcCtD
Fludarabine—DCK—Metabolism—NT5C3A—bone cancer	0.00109	0.0027	CbGpPWpGaD
Fludarabine—Angina pectoris—Epirubicin—bone cancer	0.00108	0.00185	CcSEcCtD
Fludarabine—Toxic epidermal necrolysis—Doxorubicin—bone cancer	0.00107	0.00183	CcSEcCtD
Fludarabine—Decreased appetite—Cisplatin—bone cancer	0.00107	0.00183	CcSEcCtD
Fludarabine—Bronchitis—Epirubicin—bone cancer	0.00107	0.00183	CcSEcCtD
Fludarabine—Pneumonia—Methotrexate—bone cancer	0.00106	0.00182	CcSEcCtD
Fludarabine—Gastrointestinal disorder—Cisplatin—bone cancer	0.00106	0.00182	CcSEcCtD
Fludarabine—Pancytopenia—Epirubicin—bone cancer	0.00105	0.0018	CcSEcCtD
Fludarabine—Pain—Cisplatin—bone cancer	0.00105	0.0018	CcSEcCtD
Fludarabine—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.00105	0.0018	CcSEcCtD
Fludarabine—POLA1—Mitotic G1-G1/S phases—RB1—bone cancer	0.00105	0.0026	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	0.00104	0.00259	CbGpPWpGaD
Fludarabine—Renal failure—Methotrexate—bone cancer	0.00104	0.00178	CcSEcCtD
Fludarabine—Neutropenia—Epirubicin—bone cancer	0.00104	0.00178	CcSEcCtD
Fludarabine—Dysuria—Epirubicin—bone cancer	0.00104	0.00178	CcSEcCtD
Fludarabine—Upper respiratory tract infection—Epirubicin—bone cancer	0.00103	0.00177	CcSEcCtD
Fludarabine—Stomatitis—Methotrexate—bone cancer	0.00103	0.00177	CcSEcCtD
Fludarabine—Dysphagia—Doxorubicin—bone cancer	0.00103	0.00176	CcSEcCtD
Fludarabine—Feeling abnormal—Cisplatin—bone cancer	0.00101	0.00173	CcSEcCtD
Fludarabine—Haematuria—Methotrexate—bone cancer	0.00101	0.00173	CcSEcCtD
Fludarabine—Hyperglycaemia—Epirubicin—bone cancer	0.001	0.00171	CcSEcCtD
Fludarabine—Angina pectoris—Doxorubicin—bone cancer	0.001	0.00171	CcSEcCtD
Fludarabine—Epistaxis—Methotrexate—bone cancer	0.000998	0.00171	CcSEcCtD
Fludarabine—Pneumonia—Epirubicin—bone cancer	0.000996	0.0017	CcSEcCtD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—TP53—bone cancer	0.000994	0.00247	CbGpPWpGaD
Fludarabine—Bronchitis—Doxorubicin—bone cancer	0.000988	0.00169	CcSEcCtD
Fludarabine—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000982	0.00168	CcSEcCtD
Fludarabine—Pancytopenia—Doxorubicin—bone cancer	0.000976	0.00167	CcSEcCtD
Fludarabine—Renal failure—Epirubicin—bone cancer	0.000974	0.00167	CcSEcCtD
Fludarabine—Body temperature increased—Cisplatin—bone cancer	0.000972	0.00166	CcSEcCtD
Fludarabine—Neuropathy peripheral—Epirubicin—bone cancer	0.000971	0.00166	CcSEcCtD
Fludarabine—Stomatitis—Epirubicin—bone cancer	0.000965	0.00165	CcSEcCtD
Fludarabine—Urinary tract infection—Epirubicin—bone cancer	0.000963	0.00165	CcSEcCtD
Fludarabine—Dysuria—Doxorubicin—bone cancer	0.000961	0.00164	CcSEcCtD
Fludarabine—Neutropenia—Doxorubicin—bone cancer	0.000961	0.00164	CcSEcCtD
Fludarabine—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000955	0.00163	CcSEcCtD
Fludarabine—Haemoglobin—Methotrexate—bone cancer	0.000955	0.00163	CcSEcCtD
Fludarabine—Haemorrhage—Methotrexate—bone cancer	0.00095	0.00163	CcSEcCtD
Fludarabine—Haematuria—Epirubicin—bone cancer	0.000944	0.00162	CcSEcCtD
Fludarabine—Pharyngitis—Methotrexate—bone cancer	0.000943	0.00161	CcSEcCtD
Fludarabine—Epistaxis—Epirubicin—bone cancer	0.000934	0.0016	CcSEcCtD
Fludarabine—Sinusitis—Epirubicin—bone cancer	0.000929	0.00159	CcSEcCtD
Fludarabine—Hyperglycaemia—Doxorubicin—bone cancer	0.000927	0.00159	CcSEcCtD
Fludarabine—Pneumonia—Doxorubicin—bone cancer	0.000922	0.00158	CcSEcCtD
Fludarabine—Visual impairment—Methotrexate—bone cancer	0.000916	0.00157	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.000912	0.00227	CbGpPWpGaD
Fludarabine—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000909	0.00155	CcSEcCtD
Fludarabine—Hypersensitivity—Cisplatin—bone cancer	0.000906	0.00155	CcSEcCtD
Fludarabine—Renal failure—Doxorubicin—bone cancer	0.000901	0.00154	CcSEcCtD
Fludarabine—Erythema multiforme—Methotrexate—bone cancer	0.000898	0.00154	CcSEcCtD
Fludarabine—Neuropathy peripheral—Doxorubicin—bone cancer	0.000898	0.00154	CcSEcCtD
Fludarabine—Haemoglobin—Epirubicin—bone cancer	0.000894	0.00153	CcSEcCtD
Fludarabine—Stomatitis—Doxorubicin—bone cancer	0.000893	0.00153	CcSEcCtD
Fludarabine—Urinary tract infection—Doxorubicin—bone cancer	0.000891	0.00152	CcSEcCtD
Fludarabine—Haemorrhage—Epirubicin—bone cancer	0.000889	0.00152	CcSEcCtD
Fludarabine—Hypoaesthesia—Epirubicin—bone cancer	0.000885	0.00151	CcSEcCtD
Fludarabine—Asthenia—Cisplatin—bone cancer	0.000883	0.00151	CcSEcCtD
Fludarabine—Pharyngitis—Epirubicin—bone cancer	0.000882	0.00151	CcSEcCtD
Fludarabine—Haematuria—Doxorubicin—bone cancer	0.000874	0.0015	CcSEcCtD
Fludarabine—Epistaxis—Doxorubicin—bone cancer	0.000864	0.00148	CcSEcCtD
Fludarabine—Sinusitis—Doxorubicin—bone cancer	0.00086	0.00147	CcSEcCtD
Fludarabine—Visual impairment—Epirubicin—bone cancer	0.000857	0.00147	CcSEcCtD
Fludarabine—Chills—Methotrexate—bone cancer	0.000852	0.00146	CcSEcCtD
Fludarabine—Diarrhoea—Cisplatin—bone cancer	0.000842	0.00144	CcSEcCtD
Fludarabine—Erythema multiforme—Epirubicin—bone cancer	0.000841	0.00144	CcSEcCtD
Fludarabine—POLA1—Cell Cycle, Mitotic—DHFR—bone cancer	0.00084	0.00209	CbGpPWpGaD
Fludarabine—Alopecia—Methotrexate—bone cancer	0.00084	0.00144	CcSEcCtD
Fludarabine—Malnutrition—Methotrexate—bone cancer	0.000827	0.00142	CcSEcCtD
Fludarabine—Haemoglobin—Doxorubicin—bone cancer	0.000827	0.00141	CcSEcCtD
Fludarabine—Haemorrhage—Doxorubicin—bone cancer	0.000823	0.00141	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	0.00082	0.00204	CbGpPWpGaD
Fludarabine—Hypoaesthesia—Doxorubicin—bone cancer	0.000819	0.0014	CcSEcCtD
Fludarabine—Pharyngitis—Doxorubicin—bone cancer	0.000816	0.0014	CcSEcCtD
Fludarabine—Chills—Epirubicin—bone cancer	0.000798	0.00137	CcSEcCtD
Fludarabine—Arrhythmia—Epirubicin—bone cancer	0.000794	0.00136	CcSEcCtD
Fludarabine—Visual impairment—Doxorubicin—bone cancer	0.000793	0.00136	CcSEcCtD
Fludarabine—Alopecia—Epirubicin—bone cancer	0.000786	0.00134	CcSEcCtD
Fludarabine—Vomiting—Cisplatin—bone cancer	0.000782	0.00134	CcSEcCtD
Fludarabine—Erythema multiforme—Doxorubicin—bone cancer	0.000778	0.00133	CcSEcCtD
Fludarabine—Rash—Cisplatin—bone cancer	0.000776	0.00133	CcSEcCtD
Fludarabine—Dermatitis—Cisplatin—bone cancer	0.000775	0.00133	CcSEcCtD
Fludarabine—Malnutrition—Epirubicin—bone cancer	0.000774	0.00132	CcSEcCtD
Fludarabine—Ill-defined disorder—Methotrexate—bone cancer	0.000767	0.00131	CcSEcCtD
Fludarabine—Anaemia—Methotrexate—bone cancer	0.000764	0.00131	CcSEcCtD
Fludarabine—POLA1—Cell Cycle—DHFR—bone cancer	0.000751	0.00187	CbGpPWpGaD
Fludarabine—Malaise—Methotrexate—bone cancer	0.000746	0.00128	CcSEcCtD
Fludarabine—Leukopenia—Methotrexate—bone cancer	0.00074	0.00127	CcSEcCtD
Fludarabine—Chills—Doxorubicin—bone cancer	0.000738	0.00126	CcSEcCtD
Fludarabine—Arrhythmia—Doxorubicin—bone cancer	0.000735	0.00126	CcSEcCtD
Fludarabine—Nausea—Cisplatin—bone cancer	0.000731	0.00125	CcSEcCtD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—TP53—bone cancer	0.000727	0.00181	CbGpPWpGaD
Fludarabine—Alopecia—Doxorubicin—bone cancer	0.000727	0.00124	CcSEcCtD
Fludarabine—Cough—Methotrexate—bone cancer	0.000722	0.00123	CcSEcCtD
Fludarabine—Ill-defined disorder—Epirubicin—bone cancer	0.000718	0.00123	CcSEcCtD
Fludarabine—Convulsion—Methotrexate—bone cancer	0.000717	0.00123	CcSEcCtD
Fludarabine—Malnutrition—Doxorubicin—bone cancer	0.000716	0.00123	CcSEcCtD
Fludarabine—Anaemia—Epirubicin—bone cancer	0.000715	0.00122	CcSEcCtD
Fludarabine—Agitation—Epirubicin—bone cancer	0.000711	0.00122	CcSEcCtD
Fludarabine—Arthralgia—Methotrexate—bone cancer	0.000704	0.0012	CcSEcCtD
Fludarabine—Myalgia—Methotrexate—bone cancer	0.000704	0.0012	CcSEcCtD
Fludarabine—Malaise—Epirubicin—bone cancer	0.000698	0.00119	CcSEcCtD
Fludarabine—Discomfort—Methotrexate—bone cancer	0.000696	0.00119	CcSEcCtD
Fludarabine—Leukopenia—Epirubicin—bone cancer	0.000693	0.00119	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	0.000688	0.00171	CbGpPWpGaD
Fludarabine—Confusional state—Methotrexate—bone cancer	0.000681	0.00116	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	0.000676	0.00168	CbGpPWpGaD
Fludarabine—Cough—Epirubicin—bone cancer	0.000675	0.00116	CcSEcCtD
Fludarabine—Anaphylactic shock—Methotrexate—bone cancer	0.000675	0.00115	CcSEcCtD
Fludarabine—Convulsion—Epirubicin—bone cancer	0.000671	0.00115	CcSEcCtD
Fludarabine—Infection—Methotrexate—bone cancer	0.000671	0.00115	CcSEcCtD
Fludarabine—Ill-defined disorder—Doxorubicin—bone cancer	0.000664	0.00114	CcSEcCtD
Fludarabine—Nervous system disorder—Methotrexate—bone cancer	0.000662	0.00113	CcSEcCtD
Fludarabine—Anaemia—Doxorubicin—bone cancer	0.000662	0.00113	CcSEcCtD
Fludarabine—Thrombocytopenia—Methotrexate—bone cancer	0.000661	0.00113	CcSEcCtD
Fludarabine—Arthralgia—Epirubicin—bone cancer	0.000659	0.00113	CcSEcCtD
Fludarabine—Myalgia—Epirubicin—bone cancer	0.000659	0.00113	CcSEcCtD
Fludarabine—Agitation—Doxorubicin—bone cancer	0.000658	0.00113	CcSEcCtD
Fludarabine—Hyperhidrosis—Methotrexate—bone cancer	0.000653	0.00112	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	0.000652	0.00162	CbGpPWpGaD
Fludarabine—Discomfort—Epirubicin—bone cancer	0.000651	0.00111	CcSEcCtD
Fludarabine—Malaise—Doxorubicin—bone cancer	0.000646	0.00111	CcSEcCtD
Fludarabine—Anorexia—Methotrexate—bone cancer	0.000643	0.0011	CcSEcCtD
Fludarabine—Leukopenia—Doxorubicin—bone cancer	0.000641	0.0011	CcSEcCtD
Fludarabine—Confusional state—Epirubicin—bone cancer	0.000637	0.00109	CcSEcCtD
Fludarabine—Anaphylactic shock—Epirubicin—bone cancer	0.000632	0.00108	CcSEcCtD
Fludarabine—Oedema—Epirubicin—bone cancer	0.000632	0.00108	CcSEcCtD
Fludarabine—POLA1—Cell Cycle—CHEK2—bone cancer	0.000628	0.00156	CbGpPWpGaD
Fludarabine—Infection—Epirubicin—bone cancer	0.000628	0.00107	CcSEcCtD
Fludarabine—Cough—Doxorubicin—bone cancer	0.000625	0.00107	CcSEcCtD
Fludarabine—Convulsion—Doxorubicin—bone cancer	0.00062	0.00106	CcSEcCtD
Fludarabine—Nervous system disorder—Epirubicin—bone cancer	0.000619	0.00106	CcSEcCtD
Fludarabine—Thrombocytopenia—Epirubicin—bone cancer	0.000618	0.00106	CcSEcCtD
Fludarabine—RRM1—Metabolism—ENO2—bone cancer	0.000618	0.00154	CbGpPWpGaD
Fludarabine—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000615	0.00105	CcSEcCtD
Fludarabine—Hyperhidrosis—Epirubicin—bone cancer	0.000611	0.00104	CcSEcCtD
Fludarabine—Arthralgia—Doxorubicin—bone cancer	0.00061	0.00104	CcSEcCtD
Fludarabine—Myalgia—Doxorubicin—bone cancer	0.00061	0.00104	CcSEcCtD
Fludarabine—Paraesthesia—Methotrexate—bone cancer	0.000606	0.00104	CcSEcCtD
Fludarabine—Discomfort—Doxorubicin—bone cancer	0.000602	0.00103	CcSEcCtD
Fludarabine—Anorexia—Epirubicin—bone cancer	0.000602	0.00103	CcSEcCtD
Fludarabine—Dyspnoea—Methotrexate—bone cancer	0.000602	0.00103	CcSEcCtD
Fludarabine—Dyspepsia—Methotrexate—bone cancer	0.000594	0.00102	CcSEcCtD
Fludarabine—Confusional state—Doxorubicin—bone cancer	0.000589	0.00101	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	0.000587	0.00146	CbGpPWpGaD
Fludarabine—Decreased appetite—Methotrexate—bone cancer	0.000587	0.001	CcSEcCtD
Fludarabine—Oedema—Doxorubicin—bone cancer	0.000584	0.001	CcSEcCtD
Fludarabine—Anaphylactic shock—Doxorubicin—bone cancer	0.000584	0.001	CcSEcCtD
Fludarabine—Gastrointestinal disorder—Methotrexate—bone cancer	0.000583	0.000997	CcSEcCtD
Fludarabine—Fatigue—Methotrexate—bone cancer	0.000582	0.000996	CcSEcCtD
Fludarabine—Infection—Doxorubicin—bone cancer	0.000581	0.000994	CcSEcCtD
Fludarabine—Pain—Methotrexate—bone cancer	0.000577	0.000988	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000576	0.000985	CcSEcCtD
Fludarabine—Nervous system disorder—Doxorubicin—bone cancer	0.000573	0.000981	CcSEcCtD
Fludarabine—RRM1—Metabolism—DHFR—bone cancer	0.000573	0.00142	CbGpPWpGaD
Fludarabine—Thrombocytopenia—Doxorubicin—bone cancer	0.000572	0.000979	CcSEcCtD
Fludarabine—Paraesthesia—Epirubicin—bone cancer	0.000567	0.000971	CcSEcCtD
Fludarabine—Hyperhidrosis—Doxorubicin—bone cancer	0.000565	0.000967	CcSEcCtD
Fludarabine—Dyspnoea—Epirubicin—bone cancer	0.000563	0.000964	CcSEcCtD
Fludarabine—Anorexia—Doxorubicin—bone cancer	0.000557	0.000953	CcSEcCtD
Fludarabine—Feeling abnormal—Methotrexate—bone cancer	0.000556	0.000952	CcSEcCtD
Fludarabine—Dyspepsia—Epirubicin—bone cancer	0.000556	0.000951	CcSEcCtD
Fludarabine—Decreased appetite—Epirubicin—bone cancer	0.000549	0.00094	CcSEcCtD
Fludarabine—Gastrointestinal disorder—Epirubicin—bone cancer	0.000545	0.000933	CcSEcCtD
Fludarabine—Fatigue—Epirubicin—bone cancer	0.000545	0.000932	CcSEcCtD
Fludarabine—Constipation—Epirubicin—bone cancer	0.00054	0.000924	CcSEcCtD
Fludarabine—Pain—Epirubicin—bone cancer	0.00054	0.000924	CcSEcCtD
Fludarabine—RRM1—Metabolism—GNA11—bone cancer	0.000535	0.00133	CbGpPWpGaD
Fludarabine—Body temperature increased—Methotrexate—bone cancer	0.000534	0.000913	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000533	0.000911	CcSEcCtD
Fludarabine—POLA1—Cell Cycle—BRCA2—bone cancer	0.000532	0.00132	CbGpPWpGaD
Fludarabine—Paraesthesia—Doxorubicin—bone cancer	0.000525	0.000898	CcSEcCtD
Fludarabine—Dyspnoea—Doxorubicin—bone cancer	0.000521	0.000892	CcSEcCtD
Fludarabine—Feeling abnormal—Epirubicin—bone cancer	0.000521	0.000891	CcSEcCtD
Fludarabine—Dyspepsia—Doxorubicin—bone cancer	0.000514	0.00088	CcSEcCtD
Fludarabine—POLA1—Mitotic M-M/G1 phases—RB1—bone cancer	0.000513	0.00128	CbGpPWpGaD
Fludarabine—Decreased appetite—Doxorubicin—bone cancer	0.000508	0.000869	CcSEcCtD
Fludarabine—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000505	0.000863	CcSEcCtD
Fludarabine—Fatigue—Doxorubicin—bone cancer	0.000504	0.000862	CcSEcCtD
Fludarabine—Constipation—Doxorubicin—bone cancer	0.0005	0.000855	CcSEcCtD
Fludarabine—Pain—Doxorubicin—bone cancer	0.0005	0.000855	CcSEcCtD
Fludarabine—Body temperature increased—Epirubicin—bone cancer	0.000499	0.000854	CcSEcCtD
Fludarabine—Hypersensitivity—Methotrexate—bone cancer	0.000497	0.000851	CcSEcCtD
Fludarabine—RRM1—Metabolism—CYP3A4—bone cancer	0.000485	0.00121	CbGpPWpGaD
Fludarabine—Asthenia—Methotrexate—bone cancer	0.000484	0.000829	CcSEcCtD
Fludarabine—Feeling abnormal—Doxorubicin—bone cancer	0.000482	0.000824	CcSEcCtD
Fludarabine—Pruritus—Methotrexate—bone cancer	0.000478	0.000817	CcSEcCtD
Fludarabine—DCK—Metabolism—ENO2—bone cancer	0.000475	0.00118	CbGpPWpGaD
Fludarabine—Hypersensitivity—Epirubicin—bone cancer	0.000465	0.000796	CcSEcCtD
Fludarabine—Body temperature increased—Doxorubicin—bone cancer	0.000462	0.000791	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	0.000462	0.00115	CbGpPWpGaD
Fludarabine—Diarrhoea—Methotrexate—bone cancer	0.000462	0.00079	CcSEcCtD
Fludarabine—Asthenia—Epirubicin—bone cancer	0.000453	0.000775	CcSEcCtD
Fludarabine—Pruritus—Epirubicin—bone cancer	0.000447	0.000765	CcSEcCtD
Fludarabine—POLA1—Cell Cycle, Mitotic—CDK4—bone cancer	0.000441	0.0011	CbGpPWpGaD
Fludarabine—DCK—Metabolism—DHFR—bone cancer	0.000441	0.0011	CbGpPWpGaD
Fludarabine—Diarrhoea—Epirubicin—bone cancer	0.000432	0.00074	CcSEcCtD
Fludarabine—Hypersensitivity—Doxorubicin—bone cancer	0.000431	0.000737	CcSEcCtD
Fludarabine—Vomiting—Methotrexate—bone cancer	0.000429	0.000734	CcSEcCtD
Fludarabine—Rash—Methotrexate—bone cancer	0.000426	0.000728	CcSEcCtD
Fludarabine—Dermatitis—Methotrexate—bone cancer	0.000425	0.000728	CcSEcCtD
Fludarabine—Headache—Methotrexate—bone cancer	0.000423	0.000724	CcSEcCtD
Fludarabine—Asthenia—Doxorubicin—bone cancer	0.000419	0.000718	CcSEcCtD
Fludarabine—RRM1—Metabolism—GSTP1—bone cancer	0.000415	0.00103	CbGpPWpGaD
Fludarabine—Pruritus—Doxorubicin—bone cancer	0.000414	0.000708	CcSEcCtD
Fludarabine—DCK—Metabolism—GNA11—bone cancer	0.000412	0.00102	CbGpPWpGaD
Fludarabine—Vomiting—Epirubicin—bone cancer	0.000402	0.000687	CcSEcCtD
Fludarabine—Nausea—Methotrexate—bone cancer	0.000401	0.000686	CcSEcCtD
Fludarabine—Diarrhoea—Doxorubicin—bone cancer	0.0004	0.000684	CcSEcCtD
Fludarabine—Rash—Epirubicin—bone cancer	0.000398	0.000681	CcSEcCtD
Fludarabine—Dermatitis—Epirubicin—bone cancer	0.000398	0.000681	CcSEcCtD
Fludarabine—Headache—Epirubicin—bone cancer	0.000396	0.000677	CcSEcCtD
Fludarabine—POLA1—Cell Cycle—CDK4—bone cancer	0.000395	0.000981	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	0.000388	0.000964	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—RB1—bone cancer	0.000384	0.000954	CbGpPWpGaD
Fludarabine—Nausea—Epirubicin—bone cancer	0.000375	0.000642	CcSEcCtD
Fludarabine—DCK—Metabolism—CYP3A4—bone cancer	0.000374	0.000929	CbGpPWpGaD
Fludarabine—Vomiting—Doxorubicin—bone cancer	0.000372	0.000636	CcSEcCtD
Fludarabine—Rash—Doxorubicin—bone cancer	0.000369	0.000631	CcSEcCtD
Fludarabine—Dermatitis—Doxorubicin—bone cancer	0.000368	0.00063	CcSEcCtD
Fludarabine—Headache—Doxorubicin—bone cancer	0.000366	0.000627	CcSEcCtD
Fludarabine—Nausea—Doxorubicin—bone cancer	0.000347	0.000594	CcSEcCtD
Fludarabine—POLA1—Cell Cycle—RB1—bone cancer	0.000343	0.000853	CbGpPWpGaD
Fludarabine—DCK—Metabolism—GSTP1—bone cancer	0.00032	0.000794	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—MDM2—bone cancer	0.000293	0.000727	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PTGS2—bone cancer	0.000215	0.000535	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—TP53—bone cancer	0.000168	0.000417	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PTGS2—bone cancer	0.000166	0.000412	CbGpPWpGaD
